## Phospho-Stat5 (Tyr694) (B5) rabbit mAb


www.abwizbio.com Support: info@abwizbio.com Order: sales@abwizbio.com

Catalog: #2251 Store at: -20°C


For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk
Format:	Unconjugated		
Cross Reactivity:	Predicted to work with mouse, rat and other homologues.		
Formulation:	1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA		
Preparation:	Protein A+G		
Reactivity:	Human,Mouse		
Recommended Usage:	$1.00$ - $0.001~\mu\text{g/mL}.$ It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.		
Immunogen:	A synthetic phospho-peptide corresponding to residues surrounding Tyr694 of human phospho Stat5		
Description:	Stat5 activation occurs in response growth hormone, and GM-CSF. Tyre Stat5 (1,2), and is mediated by Src Stat5 is constitutively active in som is found in some endothelial cells winvolvement in cell motility and and encoded by two separate genes, Stamino acid sequence identity. In disindependently regulated and activativates Stat5a in Predominantly activates Stat5a in Predomina	594 phosphorylation is ob upon erythropoietin stim ne leukemic cell types (4) when treated with IL-3, su giogenesis (5). Stat5 has tat5a and Stat5b, which s fferent cell types, Stat5a ated. For example, interfe	oligatory activation of culation (3). Phospho, and phospho Stat5 ggesting its been shown to be hare over 90% and Stat5b are eron treatment
References:	<ol> <li>Gouilleux, F. et al. (1994) EMBO J. 13:4361-4369.</li> <li>Wakao, H. et al. (1994) EMBO J. 13:2182-2191.</li> <li>Okutani, Y. et al. (2001) Oncogene. 20:6643-6650.</li> <li>Demoulin, J.B. et al. (1999) J. Biol. Chem. 274:25855-25861.</li> <li>Dentelli, P. et al. (1999) J. Immunol. 163:2151-2159.</li> <li>Meinke, A. et al. (1996) Mol. Cell. Biol. 16:6937-6944.</li> </ol>		






Flow cytometric analysis of Ramos cells untreated (red) or treated with IFNa+IL-4+ pervanadate (green) using Phospho-Stat5(Tyr694) antibody at 0.05 ug/mL, Stat5Y694-B5 #2251, or concentration-matched rabbit (G9) mAb IgG Isotype Control #2141 for cells untreated (black) or treated with IFNa+IL-4+pervanadate (blue).




SampleID	Median : BL1-A
Pv B5 N	22518
Imat B5 N	1358
Pv B5 P	2377
lmat B5 P	2247
Pv B5	22468
lmat B5	1340
lmat 2' only	1365

Peptide blocking flow cytometric analysis of K562 cells secondary antibody only negative control (light blue) or treated with imatinib (red) or pervanadate-treated (green) or imatinib and blocked with phospho-peptide (black) or pervanadate and blocked with phospho peptide (gold) or imatinib and blocked with non-phospho peptide (dark blue) or pervanadate and blocked with non-phospho peptide (purple) using Phospho-Stat5 (Tyr694) antibody Stat5Y694-B5 at 0.1 μg/mL. Cat. #2251.



Flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (blue) or 0.1  $\mu$ g/mL of isotype control Cat. #2141 (orange) or treated with imatinib (red) or with pervanadate (green) using Phospho-Stat5 (Tyr694) antibody Stat5Y694-B5 at 0.1  $\mu$ g/mL. Cat #2251.



Flow cytometric analysis of 3T3 cells secondary antibody only negative control (blue) or treated with imatinib (red) or with pervanadate (green) using 0.1 ug/mL of Phospho-Stat5 (Tyr694) antibody Stat5Y694-B5 (Abwiz Cat. #2251) or Company C antibody at 0.4 ug/mL (manufacturer's recommended concentration).